Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Published:2012-12 Issue:12 Volume:7 Page:1807-1814
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Weickhardt Andrew J.,Scheier Benjamin,Burke Joseph Malachy,Gan Gregory,Lu Xian,Bunn Paul A.,Aisner Dara L.,Gaspar Laurie E.,Kavanagh Brian D.,Doebele Robert C.,Camidge D. Ross

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference59 articles.

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

Cited by 577 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs;BMC Cancer;2024-08-26

3. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

4. Treatment sequences in EGFR mutant advanced NSCLC;Lung Cancer;2024-08

5. Lokaltherapie im Stadium IV bei Oligopersistenz oder Progression;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08